Chemotherapy Induced Diarrhea Market Size in the 7MM accounted for ~USD 80 Million in 2022 | Major Companies- AzuRx BioPharma, OnQuality Pharmaceuticals, Immunic Therapeutics, Napo Pharmaceuticals [Jaguar Health], and Others

The Chemotherapy-induced Diarrhea Market Size shall grow during the forecast period (2022-2032) owing to the launch of upcoming therapies, the high prevalence of Chemotherapy-induced Diarrhea, advances in pharmacological treatment, personalized treatment approach, advances in models of an Chemotherapy-induced Diarrhea, and others during the forecast period (2022-2032).

The Chemotherapy-induced Diarrhea market report provides current treatment practices, emerging drugs, Chemotherapy induced diarrhea market share of the individual therapies, and current and forecasted Chemotherapy induced diarrhea market Size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chemotherapy induced diarrhea treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from Chemotherapy-induced Diarrhea Market Research Report

• The total Chemotherapy-Induced Diarrhea market size in the United States was USD 40 million in 2022.

• In EU4 and the UK, the total Chemotherapy-Induced Diarrhea market size was found to be USD 25 million in 2022.

• In Japan, the total Chemotherapy-Induced Diarrhea market size was found to be USD 15 million in 2022.

• The leading Chemotherapy-induced Diarrhea Market Companies include AzuRx BioPharma, OnQuality Pharmaceuticals, Immunic Therapeutics, Napo Pharmaceuticals [Jaguar Health], and Others

• Promising Chemotherapy-induced Diarrhea Pipeline Therapies include FW-420, OQL051, IMU-856, MYTESI/crofelemer, and others.

To explore more information of the latest breakthroughs of Chemotherapy-induced Diarrhea Treatment Landscape, click here for Chemotherapy-induced Diarrhea Market Size @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy-induced Diarrhea Overview
Chemotherapy-induced diarrhea , also called chemotherapy-related diarrhea, can be associated with various chemotherapy agents but is most commonly described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan. Diarrhea is the dose-limiting and major toxicity of regimens containing a fluoropyrimidine with irinotecan.

Chemotherapy-induced Diarrhea Epidemiology Segmentation in the 7MM

• Chemotherapy-induced Diarrhea Diagnosed and Treatable Cases

• Total Chemotherapy-induced Diarrhea Prevalence

• Chemotherapy-induced Diarrhea Severity-Specific Prevalence

• Total Prevalence of Chemotherapy-Induced Diarrhea based on Chemotherapeutic regimen

To know more information of the Chemotherapy-induced Diarrhea Epidemiology Segmentation of the report, click here for Chemotherapy-induced Diarrhea Epidemiology Insights @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy-induced diarrhea Emerging Drugs Profile

• MYTESI/crofelemer (Napo Pharmaceuticals [Jaguar Health])
Crofelemer is an investigational drug developed by Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health in California, to treat secretory diarrhea from various causes. It is a novel, first-in-class antisecretory agent that normalizes electrolyte and fluid balance while acting locally in the gut. This mechanism of action can benefit multiple disorders that cause gastrointestinal distress, including diarrhea and abdominal discomfort. This antidiarrheal agent is an isolated and purified compound extracted from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri (Euphorbiaceae) tree found in South America and works through two separate channels associated with chloride and fluid secretion in the GI tract. Based on its mechanism of blocking chloride ion secretion through CFTR and CACC, crofelemer is being investigated in diarrhea (with multiple causative factors, including cancer therapy-related diarrhea) and has also been approved for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Currently, the company is investigating the drug in Phase III clinical trial, evaluating crofelemer for diarrhea prophylaxis in adult patients with solid tumors receiving targeted-cancer therapies with or without standard chemotherapy. Moreover, in February 2022, Jaguar Health and Napo Therapeutics announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the EMA.

Chemotherapy-induced Diarrhea Market Outlook

According to an international, cross-sectional survey among European oncologists by Kordes and Gerling (2019), the recommended initial approach to the patient with severe Chemotherapy induced diarrhea generally includes hospital admission, IV fluids, and the opioid-receptor agonist, loperamide, to regulate gut motility. However, evidence from randomized controlled trials for the use and dosage of loperamide is limited, and recommendations are largely based on expert opinion and clinical experience, as well as extrapolated from data from the treatment of diarrhea in other clinical settings, such as irritable bowel disease. In therapy-refractory cases, the somatostatin analog, octreotide, has been recommended based on a Phase I trial and a small study conducted in the 1990s comparing octreotide to loperamide. Beyond these evidence-based recommendations, data on Chemotherapy induced diarrhea management are sparse, reflected in the limited overall strength of guideline recommendations.

Browse More Related Reports of the Chemotherapy-induced Diarrhea Market Research Reports, click here for Chemotherapy-induced Diarrhea Market Forecast @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chemotherapy-induced Diarrhea Market Research Report

• Coverage- 7MM

• Chemotherapy-induced Diarrhea Companies- AzuRx BioPharma, OnQuality Pharmaceuticals, Immunic Therapeutics, Napo Pharmaceuticals [Jaguar Health], and Others

• Chemotherapy-induced Diarrhea Pipeline Therapies- FW-420, OQL051, IMU-856, MYTESI/crofelemer, and others.
• Chemotherapy-induced Diarrhea Market Dynamics: Chemotherapy-induced Diarrhea Market Drivers and Barriers

• Chemotherapy-induced Diarrhea Market Access and Reimbursement, Unmet Needs, Future Perspective

Read the Full Research Report of the Chemotherapy-induced Diarrhea Market Forecast Report, click here for Chemotherapy-induced Diarrhea Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Key Insights
2. Chemotherapy-induced Diarrhea Report Introduction
3. Chemotherapy-induced Diarrhea Market Overview at a Glance
4. Chemotherapy-induced Diarrhea Executive Summary
5. Chemotherapy-induced Diarrhea Epidemiology and Market Methodology
6. Chemotherapy-induced Diarrhea Disease Background and Overview
7. Chemotherapy-induced Diarrhea Epidemiology and Patient Population
8. Chemotherapy-induced Diarrhea Patient Journey
9. Key Endpoints in Chemotherapy-induced Diarrhea Clinical Trials
10. Chemotherapy-induced Diarrhea Emerging Therapies
11. Chemotherapy-induced Diarrhea: 7MM Analysis
12. KOL Views
13. Chemotherapy-induced Diarrhea SWOT Analysis
14. Chemotherapy-induced Diarrhea Unmet Needs
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

Consult with our Business Expert @ Chemotherapy-induced Diarrhea Market Landscape- https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.